Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology

The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase I-II trials (main...

Full description

Bibliographic Details
Main Authors: Daniel A. Jones, Fizzah Choudry, Anthony Mathur
Format: Article
Language:English
Published: Elsevier 2013-04-01
Series:Revista Portuguesa de Cardiologia
Online Access:http://www.sciencedirect.com/science/article/pii/S0870255113000498
id doaj-ee4a3400007d4758aa971c6b7fccffd2
record_format Article
spelling doaj-ee4a3400007d4758aa971c6b7fccffd22020-11-25T01:30:46ZengElsevierRevista Portuguesa de Cardiologia0870-25512013-04-01324351358Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiologyDaniel A. Jones0Fizzah Choudry1Anthony Mathur2Department of Cardiology, London Chest Hospital, London, UK; Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK; NIHR Cardiovascular Biomedical Research Unit, London Chest Hospital, London, UKDepartment of Cardiology, London Chest Hospital, London, UK; NIHR Cardiovascular Biomedical Research Unit, London Chest Hospital, London, UKDepartment of Cardiology, London Chest Hospital, London, UK; Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK; NIHR Cardiovascular Biomedical Research Unit, London Chest Hospital, London, UK; Corresponding author.The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase I-II trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing ‘activity’ in numerous published meta-analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the ‘engineered’ cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.http://www.sciencedirect.com/science/article/pii/S0870255113000498
collection DOAJ
language English
format Article
sources DOAJ
author Daniel A. Jones
Fizzah Choudry
Anthony Mathur
spellingShingle Daniel A. Jones
Fizzah Choudry
Anthony Mathur
Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology
Revista Portuguesa de Cardiologia
author_facet Daniel A. Jones
Fizzah Choudry
Anthony Mathur
author_sort Daniel A. Jones
title Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology
title_short Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology
title_full Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology
title_fullStr Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology
title_full_unstemmed Almanac 2012: Cell therapy in cardiovascular disease. The national society journals present selected research that has driven recent advances in clinical cardiology
title_sort almanac 2012: cell therapy in cardiovascular disease. the national society journals present selected research that has driven recent advances in clinical cardiology
publisher Elsevier
series Revista Portuguesa de Cardiologia
issn 0870-2551
publishDate 2013-04-01
description The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase I-II trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing ‘activity’ in numerous published meta-analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the ‘engineered’ cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.
url http://www.sciencedirect.com/science/article/pii/S0870255113000498
work_keys_str_mv AT danielajones almanac2012celltherapyincardiovasculardiseasethenationalsocietyjournalspresentselectedresearchthathasdrivenrecentadvancesinclinicalcardiology
AT fizzahchoudry almanac2012celltherapyincardiovasculardiseasethenationalsocietyjournalspresentselectedresearchthathasdrivenrecentadvancesinclinicalcardiology
AT anthonymathur almanac2012celltherapyincardiovasculardiseasethenationalsocietyjournalspresentselectedresearchthathasdrivenrecentadvancesinclinicalcardiology
_version_ 1725090032828547072